Hoya Vision Care

The new HOYA Learning Center™ is now live. Empower your team's potential and elevate every part of your practice with courses designed by experts: https://bit.ly/4hmqQP9

Every child deserves to feel confident, whether in the classroom, on the court, or simply exploring the world around them. But for kids with myopia, it makes those everyday moments harder to navigate.   At HOYA Vision Care, we believe in empowering children through clear vision. MiYOSMART** spectacle lenses were developed specifically for young patients with progressing myopia. Backed by research and proven effective for over 8 years*.   As Eye Care Professionals, you can lead the way in myopia management, making a lasting difference in children's lives. Open their World.   *DISCLAIMER: Leung et al. Comparison of Myopia Progression in Individuals Wearing Defocus Incorporated Multiple Segments (DIMS) Spectacle Lenses for Eight Years versus Shorter Durations. Abstract presented at ARVO 2025. Product Disclaimer: **MiYOSMART myopia control spectacle lenses have not been approved for use in the management of myopia in all countries, including the U.S., and are not currently available for sale in all countries, including the U.S.   #MiYOSMART #OpenTheirWorld #MyopiaManagement #VisionCare #ChildEyeHealth #Optometry #EmpowerVision #EyeCareProfessionals #HOYAVisionCareGlobal

We’re proud to be a Gold Sponsor at the 50th European Paediatric Ophthalmological Society (EPOS) – Team- and Network in Paediatric Ophthalmology, a key platform uniting leading experts and innovators dedicated to protecting and improving children’s eye health.   As the global rise in childhood myopia continues to accelerate, collaboration, research, and evidence-based solutions have never been more essential. At HOYA Vision Care, we are deeply committed to advancing scientific understanding and developing innovative technologies that help slow the progression of myopia and support better visual outcomes for children.   Through continuous research, strong partnerships, and cutting-edge innovations like MiYOSMART*, we aim to empower eye care professionals and families with tools that make a lasting difference in children’s eye health.   We look forward to connecting with peers and partners at EPOS 2025 as we continue shaping the future of myopia management, together.   #EPOS2025 #MyopiaManagement #ChildrensVision #EyeHealth #Ophthalmology #MiYOSMART #PaediatricOphthalmology #HOYAVisionCareGlobal Product Disclaimer: *MiYOSMART spectacle lenses have not been approved for myopia management in all countries, including the United States, and are not currently available for sale in all countries.

At EVER EVER 2025, we’re proud to showcase research that advances our understanding of myopia management. The Poster Sessions will highlight key findings from international experts, addressing combination treatments, compliance, and new insights into myopia progression. 📅 October 9, 2025 📍 Palazzo degli Affari, Florence Topics & Presentors: - Choroidal thickness changes in myopic children using combination treatment of atropine eyedrops and defocus incorporated multiple segments (DIMS) spectacle lenses by Noemi Guemes-Villahoz, Ophthalmologist and Researcher, Hospital Clinico San Carlos de Madrid, Spain - Atropine and spectacle lens combination treatment (ASPECT): 24-month interim results of a randomized controlled trial for myopia control by Noemi Guemes, Ophthalmologist and Researcher, Hospital Clinico San Carlos de Madrid, Spain - Effectiveness of DIMS spectacle lenses on myopia control in Romanian children: 2-year results – Daniela Goicea, Ophthalmologist, Coordinator of the Romanian Section of EurOK - The importance of treatment compliance in myopia control: a retrospective study – Irene Schiavetti, Assistant Professor in Biostatistics, University of Genoa, Italy - The role of astigmatism in myopia, its progression and management: a scoping review – Stephanie Kearney, Optometrist & Senior Lecturer, Glasgow Caledonian University, UK   We look forward to sharing insights, exchanging knowledge, and advancing the conversation on myopia management at EVER 2025. Register now: https://lnkd.in/eFH7RZt5 #HOYAVisionCare #MyopiaManagement #EVER2025 #Innovation #ConfidenceThroughEvidence #Miyosmart #HoyaVisionCareGlobal Product Disclaimer: MiYOSMART spectacle lenses have not been approved for myopia management in all countries, including the United States, and are not currently available for sale in all countries.

Join us on 6 October at 19:00 CET for our webinar “Confidence in Practice, Confidence in MiYOSMART” and discover the latest insights and trends in childhood myopia management. Don’t miss this opportunity to strengthen your expertise and confidence in practice. Register now - https://lnkd.in/dPAaKZQG Let’s shape the future of myopia management, together. We look forward to welcoming you! #MiYOSMART #MyopiaManagement #ConfidenceInPractice #Ophthalmology #Optometry #EyeCareProfessionals #EMEA #ChildVisionCare #ClinicalEducation #HOYAVisionCareGlobal Product Disclaimer: *MiYOSMART spectacle lenses have not been approved for myopia management in all countries, including the United States, and are not currently available for sale in all countries.

At HOYA Vision Care, we are committed to improving life through vision. Every step of the way, we strive to innovate so that patients can enjoy the best possible quality of life. This week, we are proud to celebrate a remarkable milestone: our colleagues at Hoya Lens Italia have been awarded the “Best Project to Support Community Health” at the #Forbes ESG Pharma Awards 2025. This recognition highlights not only the technological innovation behind #MiYOSMART**, the world’s first prescription spectacle lens with D.I.M.S. Technology, but also the profound social value of a project that protects children’s eyesight and raises awareness among families about myopia. Backed by the world’s longest-running 8-year follow-up* study in myopia management spectacle lenses to date, MiYOSMART is helping safeguard the long-term visual well-being of young people. This award is a recognition of our purpose in action “Improve life through vision”. #Forbes #ESG #MiYOSMART #MyopiaManagement #HOYAVisionCare #Actnow #ImprouveLiveThroughVision * Leung TW, et al. Comparison of Myopia Progression in Individuals Wearing Defocus Incorporated Multiple Segments (DIMS) Spectacle Lenses for Eight Years versus Shorter Durations. Poster number A0113. Presented 6th May, ARVO 2025   Product Disclaimer: **MiYOSMART spectacle lenses have not been approved for myopia management in all countries, including the United States, and are not currently available for sale in all countries.

We’re excited to participate in the Rapid Fire sessions at EVER 2025 in Florence, where leading experts will share the latest evidence and insights in myopia management. These presentations are designed to spark discussion and showcase innovation that drives better eye care for children worldwide. 📅 October 9, 2025 | 16:50 – 18:05 📍Palazzo degli Affari, Florence | Hall 3.1 Topics & Speakers: - Choroidal thickness changes in myopic children using combination treatment of atropine eyedrops and defocus incorporated multiple segments (DIMS) spectacle lenses by Noemi Guemes-Villahoz, Ophthalmologist and Researcher, Hospital Clinico San Carlos de Madrid, Spain - Atropine and spectacle lens combination treatment (ASPECT): 24-month interim results of a randomized controlled trial for myopia control by Noemi Guemes, Ophthalmologist and Researcher, Hospital Clinico San Carlos de Madrid, Spain - The role of astigmatism in myopia, its progression and management: a scoping review by Dr. Stephanie Kearney, Optometrist & Senior Lecturer, Glasgow Caledonian University, UK Register now: https://lnkd.in/eFH7RZt5 Join us and discover the latest research findings and explore how evidence-based solutions can transform myopia management globally. #HOYAVisionCare #MyopiaManagement #EVER2025 #Innovation #ConfidenceThroughEvidence #Miyosmart #HoyaVisionCareGlobal Product Disclaimer: *MiYOSMART myopia control spectacle lenses have not been approved for use in the management of myopia in all countries, including the U.S., and are not currently available for sale in all countries, including the U.S.  

At HOYA Vision Care, we are committed to improve life through vision by translating scientific evidence and insights into real-world impact. With myopia rising at unprecedented rates, we are committed to providing evidence-based solutions that empower eye care professionals to protect the future of children’s eyesight. As part of our commitment, we are proud to host a dedicated Lunch Symposium at EVER EVER 2025 in Florence, bringing together leading experts to explore the role of DIMS spectacle lenses in successful myopia management. This session will combine scientific evidence with practical experience, highlighting how innovation is transforming children’s vision care worldwide. 📅 October 10, 2025 | 13:05 – 14:05 📍 Location: Palazzo degli Affari, Florence | Room B Programme Highlights: -MiYOSMART: Where Evidence Meets Confidence in Myopia Management by Matilde Ronzoni, Global Medical Affairs Manager, HOYA Vision Care -Why myopia matters: multiple approaches for successful management by Noemi Guemes-Villahoz Guemes, Ophthalmologist & Researcher, Hospital Clinico San Carlos de Madrid, Spain -Theory meets practice: exploring real-world case studies by Daniela Goicea, Ophthalmologist, Coordinator of the Romanian Section of EurOK Join us at the symposium to hear from global experts, exchange insights, and explore how science and practice come together to improve lives through better vision. Register now: https://lnkd.in/eFH7RZt5 #HOYAVisionCare #MyopiaManagement #EVER2025 #Innovation #ConfidenceThroughEvidence #Miyosmart #HoyaVisionCareGlobal Product Disclaimer: *MiYOSMART myopia control spectacle lenses have not been approved for use in the management of myopia in all countries, including the U.S., and are not currently available for sale in all countries, including the U.S.  

At HOYA Vision Care, we believe every child deserves the chance to reach their full potential.   As a child, he loved being on the tennis court, but his progressing myopia made it harder to play with the same ease as before. He started to feel less sure of himself, and his confidence quietly began to fade. But things started to shift when he was fitted with MiYOSMART spectacle lenses. Today, he looks back and remembers how it helped him not just stay in the game, but thrive. View the film - https://lnkd.in/dpwvekPX Clinically proven to slow down myopia progression for over 8 years*, MiYOSMART offers a science-backed, non-invasive solution that supports long-term eye health. As Eye Care Professionals, you can lead the way in myopia management, making a lasting difference in children's lives. September is Myopia Action Month and a perfect moment to remember the impact you have on the lives of young patients. Open their World. #MiYOSMART #OpenTheirTalent #MyopiaManagement #VisionCare #ChildEyeHealth #Optometry #EmpowerVision #EyeCareProfessionals #HOYAVisionCareGlobal *DISCLAIMER: Leung et al. Comparison of Myopia Progression in Individuals Wearing Defocus Incorporated Multiple Segments (DIMS) Spectacle Lenses for Eight Years versus Shorter Durations. Abstract presented at ARVO 2025. Product Disclaimer: **MiYOSMART spectacle lenses have not been approved for myopia management in all countries, including the United States, and are not currently available for sale in all countries.  

At HOYA Vision Care, we are committed to advancing evidence-based solutions for myopia management and bringing better vision to children worldwide. We are proud to be part of the 28th EVER EVER Congress 2025, one of Europe’s leading congresses for research and innovation in eye health science. Our experts will be presenting cutting-edge evidence and real-world insights on myopia management, including the impact of DIMS spectacle lenses and combination treatments with atropine. Join us for our HOYA Lunch Symposium:  MiYOSMART: Where Evidence Meets Practice: DIMS Spectacle Lenses For Successful Myopia Management on 10th October. Don’t miss out Posters & Rapid Fire Sessions on October 9, 2025 Location: Palazzo degli Affari, Florence We look forward to sharing insights, exchanging knowledge, and advancing the conversation on myopia management at EVER 2025. Register now: https://lnkd.in/eFH7RZt5 #HOYAVisionCare #MyopiaManagement #EVER2025 #Innovation #ConfidenceThroughEvidence #Miyosmart #HoyaVisionCareGlobal Product Disclaimer: MiYOSMART myopia control spectacle lenses have not been approved for use in the management of myopia in all countries, including the U.S., and are not currently available for sale in all countries, including the U.S.